Slingshot members are tracking this event:

Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for patients with untreated (treatment-naïve) acute myeloid leukemia (AML) who are ineligible to receive standard induction therapy (high-dose chemotherapy)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The Breakthrough Therapy Designation is supported by data from untreated patients, 65 years or older with AML and reported in one investigational study. AML is typically treated with chemotherapy and the intensity of chemotherapy depends on a person's age and health. However, no single standard of care exists for older patients with AML, as there are no FDA- approved therapies for patients not eligible to receive standard induction therapy/intensive chemotherapy. Because induction-therapy-related mortality for patients 55 years of age or older has been estimated at 15 to 20 percent, these patients are best managed with non-intensive approaches.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Venetoclax, Breakthrough Therapy Designation, Fda